Cancer Genetics (CGIX) Tops Q1 EPS by 10c

Cancer Genetics (NASDAQ: CGIX) reported Q1 EPS of ($0.44), $0.10 better than the analyst estimate of ($0.54). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $3.91 million.

For earnings history and earnings-related data on Cancer Genetics (CGIX) click here.

You May Also Be Interested In

• Cerebras CEO says investors misunderstood margin guidance
• Morgan Stanley raises dividend 15% and approves $20B buyback program
• Hertz cuts guidance, announces notes and stock offerings, shares sink